Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Morton

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Blood|February 22, 2013
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variantJenny McIntosh, Peter J Lenting, Cecilia Rosales, et al.
Nature Communications|December 22, 2019
Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumorAndrew J Murphy, Xiang Chen, Emilia M Pinto, et al.
The New England Journal of Medicine|June 11, 2025
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BUlrike M Reiss, Andrew M Davidoff, Edward G D Tuddenham, et al.
The New England Journal of Medicine|November 20, 2014
Long-term safety and efficacy of factor IX gene therapy in hemophilia BAmit C Nathwani, Ulreke M Reiss, Edward G D Tuddenham, et al.
The New England Journal of Medicine|December 14, 2011
Adenovirus-associated virus vector-mediated gene transfer in hemophilia BAmit C Nathwani, Edward G D Tuddenham, Savita Rangarajan, et al.
Research Square|March 30, 2023
The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q StudyAndrew J Murphy, Changde Cheng, Justin Williams, et al.
Nature Communications|December 18, 2023
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-QAndrew J Murphy, Changde Cheng, Justin Williams, et al.
Nature Communications|September 17, 2025
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticityShivendra Singh, Jie Fang, Hongjian Jin, et al.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Cell Reports|March 18, 2026
Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumorAndrew M Fleming, Carolyn M Jablonowski, Hongjian Jin, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Blood|February 22, 2013
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variantJenny McIntosh, Peter J Lenting, Cecilia Rosales, et al.
Nature Communications|December 22, 2019
Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumorAndrew J Murphy, Xiang Chen, Emilia M Pinto, et al.
The New England Journal of Medicine|June 11, 2025
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BUlrike M Reiss, Andrew M Davidoff, Edward G D Tuddenham, et al.
The New England Journal of Medicine|November 20, 2014
Long-term safety and efficacy of factor IX gene therapy in hemophilia BAmit C Nathwani, Ulreke M Reiss, Edward G D Tuddenham, et al.
The New England Journal of Medicine|December 14, 2011
Adenovirus-associated virus vector-mediated gene transfer in hemophilia BAmit C Nathwani, Edward G D Tuddenham, Savita Rangarajan, et al.
Research Square|March 30, 2023
The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q StudyAndrew J Murphy, Changde Cheng, Justin Williams, et al.
Nature Communications|December 18, 2023
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-QAndrew J Murphy, Changde Cheng, Justin Williams, et al.
Nature Communications|September 17, 2025
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticityShivendra Singh, Jie Fang, Hongjian Jin, et al.
Communications Biology|April 8, 2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicinKaruna Mittal, Garrett W Cooper, Benjamin P Lee, et al.
Cell Reports|March 18, 2026
Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumorAndrew M Fleming, Carolyn M Jablonowski, Hongjian Jin, et al.
Pageof 10